Format

Send to

Choose Destination
Front Biosci (Landmark Ed). 2015 Jun 1;20:1190-233.

Gene and splicing therapies for neuromuscular diseases.

Author information

1
Chair of Excellence HandiMedEx, Laboratory Biotherapies des Maladies Neuromusculaires, UFR des sciences de la sante Simone Veil, Universite de Versailles Saint Quentin, 2 Avenue de la source de la bievre, 78180 Montigny le bretonneux, France, aurelie.goyenvalle@uvsq.fr.

Abstract

Neuromuscular disorders (NMD) are heterogeneous group of genetic diseases characterized by muscle weakness and wasting. Duchenne Muscular dystrophy (DMD) and Spinal muscular atrophy (SMA) are two of the most common and severe forms in humans and although the molecular mechanisms of these diseases have been extensively investigated, there is currently no effective treatment. However, new gene-based therapies have recently emerged with particular noted advances in using conventional gene replacement strategies and RNA-based technology. Whilst proof of principle have been demonstrated in animal models, several clinical trials have recently been undertaken to investigate the feasibility of these strategies in patients. In particular, antisense mediated exon skipping has shown encouraging results and hold promise for the treatment of dystrophic muscle. In this review, we summarize the recent progress of therapeutic approaches to neuromuscular diseases, with an emphasis on gene therapy and splicing modulation for DMD and SMA, focusing on the advantages offered by these technologies but also their challenges.

PMID:
25961553
DOI:
10.2741/4367
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Frontiers in Bioscience
Loading ...
Support Center